» Articles » PMID: 36303071

Age-related Huntington's Disease Progression Modeled in Directly Reprogrammed Patient-derived Striatal Neurons Highlights Impaired Autophagy

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disorder with adult-onset clinical symptoms, but the mechanism by which aging drives the onset of neurodegeneration in patients with HD remains unclear. In this study we examined striatal medium spiny neurons (MSNs) directly reprogrammed from fibroblasts of patients with HD to model the age-dependent onset of pathology. We found that pronounced neuronal death occurred selectively in reprogrammed MSNs from symptomatic patients with HD (HD-MSNs) compared to MSNs derived from younger, pre-symptomatic patients (pre-HD-MSNs) and control MSNs from age-matched healthy individuals. We observed age-associated alterations in chromatin accessibility between HD-MSNs and pre-HD-MSNs and identified miR-29b-3p, whose age-associated upregulation promotes HD-MSN degeneration by impairing autophagic function through human-specific targeting of the STAT3 3' untranslated region. Reducing miR-29b-3p or chemically promoting autophagy increased the resilience of HD-MSNs against neurodegeneration. Our results demonstrate miRNA upregulation with aging in HD as a detrimental process driving MSN degeneration and potential approaches for enhancing autophagy and resilience of HD-MSNs.

Citing Articles

Diagnostic Value of Serum miR-499a-5p in Chinese Children with Autism Spectrum Disorders.

Ren J, Bai Y, Gao J, Hou Y, Mao J, Gao F J Mol Neurosci. 2025; 75(1):8.

PMID: 39836335 DOI: 10.1007/s12031-024-02296-2.


Fate erasure logic of gene networks underlying direct neuronal conversion of somatic cells by microRNAs.

Cates K, Yuan L, Yang Y, Yoo A Cell Rep. 2025; 44(1):115153.

PMID: 39756035 PMC: 11834941. DOI: 10.1016/j.celrep.2024.115153.


MicroRNAs regulating autophagy: opportunities in treating neurodegenerative diseases.

Mohseni M, Behzad G, Farhadi A, Behroozi J, Mohseni H, Valipour B Front Neurosci. 2024; 18:1397106.

PMID: 39582602 PMC: 11582054. DOI: 10.3389/fnins.2024.1397106.


Neuroinflammatory Proteins in Huntington's Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications.

Li X, Tong H, Xu S, Zhou G, Yang T, Yin S Int J Mol Sci. 2024; 25(21).

PMID: 39519337 PMC: 11546928. DOI: 10.3390/ijms252111787.


Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes.

Kraskovskaya N, Linkova N, Sakhenberg E, Krieger D, Polyakova V, Medvedev D Int J Mol Sci. 2024; 25(21).

PMID: 39518916 PMC: 11546785. DOI: 10.3390/ijms252111363.


References
1.
Vonsattel J, DiFiglia M . Huntington disease. J Neuropathol Exp Neurol. 1998; 57(5):369-84. DOI: 10.1097/00005072-199805000-00001. View

2.
Ross C, Aylward E, Wild E, Langbehn D, Long J, Warner J . Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014; 10(4):204-16. DOI: 10.1038/nrneurol.2014.24. View

3.
Kremer B, Goldberg P, Andrew S, Theilmann J, Telenius H, Zeisler J . A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994; 330(20):1401-6. DOI: 10.1056/NEJM199405193302001. View

4.
Brinkman R, Mezei M, Theilmann J, Almqvist E, Hayden M . The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet. 1997; 60(5):1202-10. PMC: 1712445. View

5.
Arrasate M, Mitra S, Schweitzer E, Segal M, Finkbeiner S . Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004; 431(7010):805-10. DOI: 10.1038/nature02998. View